<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Encounter Summary</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Reason for Visit</a></li><li><a href="#id2">Encounter Details</a></li><li><a href="#id3">Social History</a></li><li><a href="#id4">Last Filed Vital Signs</a></li><li><a href="#id5">Progress Notes</a></li><li><a href="#id6">Plan of Treatment</a></li><li><a href="#id7">Results</a></li><li><a href="#id8">Visit Diagnoses</a></li><li><a href="#id9">Care Teams</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Reason for Visit</a></h3><div><ul><li><table><colgroup><col width="25%"/><col width="75%"/></colgroup><thead><tr><th>Reason</th><th>Comments</th></tr></thead><tbody><tr ID="rfv2"><td ID="reasonrfv2">Follow-up</td><td ID="rfv2comments">Prostate ca</td></tr></tbody></table></li></ul></div><h3><a name="id2" href="#toc">Encounter Details</a></h3><div><table><colgroup><col width="10%"/><col width="15%"/><col width="25%" span="3"/></colgroup><thead><tr><th>Date</th><th>Type</th><th>Department</th><th>Care Team (Latest Contact Info)</th><th>Description</th></tr></thead><tbody><tr ID="encounter3" class="xRowNormal"><td>[REDACTED]  8:20 AM EDT</td><td ID="encounter3type">Office Visit</td><td><p>HCMG Cancer Center Hematology Oncology</p><p>[REDACTED]</p><p>[REDACTED]-4603</p><p>[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED]</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td><content>Prostate cancer (CMS/HCC) (Primary Dx); <br/>Abnormal findings on diagnostic imaging of other specified body structures; <br/>Abnormal results of liver function studies; <br/>Abnormal coagulation profile</content></td></tr></tbody></table></div><h3><a name="id3" href="#toc">Social History</a></h3><div><table ID="sochist11"><colgroup><col width="25%" span="2"/><col width="13%"/><col width="12%"/><col width="25%"/></colgroup><thead><tr><th>Tobacco Use</th><th>Types</th><th>Packs/Day</th><th>Years Used</th><th>Date</th></tr></thead><tbody><tr><td>Smoking Tobacco: Never Assessed</td><td/><td ID="sochist11packsperday"/><td/><td/></tr></tbody></table><table><colgroup><col width="25%" span="2"/><col width="50%"/></colgroup><thead><tr><th>Alcohol Use</th><th>Standard Drinks/Week</th><th>Comments</th></tr></thead><tbody><tr><td ID="alcoholStatus">Yes</td><td>0 (1 standard drink = 0.6 oz pure alcohol)</td><td>being a social drinker </td></tr></tbody></table><table ID="sdohassess1"><colgroup><col width="50%"/><col width="25%" span="2"/></colgroup><thead><tr><th>Interpersonal Safety</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess1pair1"><td ID="sdohassess1pair1ques">Physical Abuse</td><td ID="sdohassess1pair1ans"/><td>[REDACTED]</td></tr><tr ID="sdohassess1pair2"><td ID="sdohassess1pair2ques">Verbal Abuse</td><td ID="sdohassess1pair2ans"/><td>[REDACTED]</td></tr></tbody></table><table><colgroup><col width="50%"/><col width="25%" span="2"/></colgroup><thead><tr><th>Sex and Gender Information</th><th>Value</th><th>Date Recorded</th></tr></thead><tbody><tr ID="BirthSex14"><td>Sex Assigned at Birth</td><td ID="BirthSex14Value">Not on file</td><td/></tr><tr ID="GenderIdentity12"><td>Gender Identity</td><td ID="GenderIdentity12Value">Not on file</td><td/></tr><tr ID="SexualOrientation13"><td>Sexual Orientation</td><td ID="SexualOrientation13Value">Not on file</td><td/></tr></tbody></table><table><colgroup><col width="25%" span="2"/><col width="50%"/></colgroup><thead><tr><th>Job Start Date</th><th>Occupation</th><th>Industry</th></tr></thead><tbody><tr><td>Not on file</td><td ID="sochist15">Not on file</td><td ID="sochist16">Not on file</td></tr></tbody></table>documented as of this encounter</div><h3><a name="id4" href="#toc">Last Filed Vital Signs</a></h3><div><table><colgroup><col width="25%" span="4"/></colgroup><thead><tr><th>Vital Sign</th><th>Reading</th><th>Time Taken</th><th>Comments</th></tr></thead><tbody><tr class="xRowNormal"><td class="xcellHeader">Blood Pressure</td><td><span class="content_span">127</span>/<span class="content_span">82</span></td><td>[REDACTED]  8:39 AM EDT</td><td/></tr><tr ID="pulse_5785562340" class="xRowAlt"><td class="xcellHeader">Pulse</td><td>86</td><td>[REDACTED]  8:39 AM EDT</td><td/></tr><tr ID="temp_5785562340" class="xRowNormal"><td class="xcellHeader">Temperature</td><td>36.1 °C (97 °F)</td><td>[REDACTED]  8:39 AM EDT</td><td/></tr><tr ID="resp_5785562340" class="xRowAlt"><td class="xcellHeader">Respiratory Rate</td><td>18</td><td>[REDACTED]  8:39 AM EDT</td><td/></tr><tr ID="SpO2_5785562340" class="xRowNormal"><td class="xcellHeader">Oxygen Saturation</td><td>100%</td><td>[REDACTED]  8:39 AM EDT</td><td/></tr><tr ID="inhaled_" class="xRowAlt"><td class="xcellHeader">Inhaled Oxygen Concentration</td><td>-</td><td>-</td><td/></tr><tr ID="weight_5785562340" class="xRowNormal"><td class="xcellHeader">Weight</td><td>111 kg (245 lb)</td><td>[REDACTED]  8:39 AM EDT</td><td/></tr><tr ID="height_5785562340" class="xRowAlt"><td class="xcellHeader">Height</td><td>186.7 cm (6' 1.5")</td><td>[REDACTED]  8:39 AM EDT</td><td/></tr><tr ID="bmi_5785562340" class="xRowNormal"><td class="xcellHeader">Body Mass Index</td><td>31.89</td><td>[REDACTED]  8:39 AM EDT</td><td/></tr></tbody></table>documented in this encounter</div><h3><a name="id5" href="#toc">Progress Notes</a></h3><div><ul><li>[REDACTED], MD - [REDACTED]  8:20 AM EDT: <content><content><span class="xLabel">Formatting of this note is different from the original.</span><br/>CONSULTATION<br/>Hematology-Oncology<br/> <br/>[REDACTED]<br/>MRN: [REDACTED]<br/>Encounter Date: [REDACTED]<br/>PCP: [REDACTED], DO<br/> <br/> <br/>Chief Complaint:<br/>1. Prostate cancer (CMS/HCC)  <br/>2. Abnormal findings on diagnostic imaging of other specified body structures  <br/>3. Abnormal results of liver function studies  <br/>4. Abnormal coagulation profile  <br/><br/> <br/> <br/>HPI:<br/>[REDACTED] is a [REDACTED]. male currently self-referred for further evaluation of metastatic prostate cancer.<br/><br/>Oncology history<br/><br/>Has had metastatic cancer since at least 2016 after being diagnosed with [REDACTED] 8 prostate cancer he initially procedure was some alternative therapy when he came back MRI showed metastatic disease he has been on and off Lupron bicalutamide in the past with history of noncompliance.  Has been recommended Erleada bone modifying agent but not had not started on any other he reports that he has been taking Lupron<br/><br/>[REDACTED] PSMA PET scan confirms positive PSMA PET uptake bone metastasis no evidence of visceral metastasis NGS panel confirms as part mutation and CT abdomen B1 mutation.  High cell free DNA levels indicating aggressive disease.  Patient tolerated first cycle of chemotherapy well.  Given spop mutation we will consider adding carboplatin to further cycles after cycle 2.<br/><br/>The second 2024 patient with evidence of very good response to chemotherapy with PSA trending down to 3.2 also his Signatera has trended down to 0 from 1700.<br/> <br/>Treatment Summary:<br/>n/a<br/> <br/>No past medical history on file.<br/> <br/>No past surgical history on file.<br/> <br/>Family History <br/>Problem Relation Name Age of Onset <br/> Dementia Mother   <br/> Hypertension Mother   <br/> Alcohol abuse Father   <br/><br/> <br/>Social History <br/><br/>Socioeconomic History <br/> Marital status: Married <br/>  Spouse name: Not on file <br/> Number of children: Not on file <br/> Years of education: Not on file <br/> Highest education level: Not on file <br/>Occupational History <br/> Not on file <br/>Tobacco Use <br/> Smoking status: Not on file <br/> Smokeless tobacco: Not on file <br/>Substance and Sexual Activity <br/> Alcohol use: Yes <br/>  Comment: being a social drinker  <br/> Drug use: Not on file <br/> Sexual activity: Not on file <br/>Other Topics Concern <br/> Not on file <br/>Social History Narrative <br/> Not on file <br/><br/> <br/>Home Medication(s):<br/>has a current medication list which includes the following prescription(s): amlodipine, atorvastatin, benazepril-hydrochlorthiazide, clonidine, darolutamide, nubeqa, enulose, metformin, oxycodone-acetaminophen, prochlorperazine, alprazolam, finasteride, lisinopril-hydrochlorothiazide, sulfamethoxazole-trimethoprim, tadalafil, and tamsulosin.<br/> <br/>Allergies:<br/>No Known Allergies<br/> <br/>Review of Systems:<br/>Negative except as per HPI <br/><br/> <br/>Physical Exam:<br/>Vitals: <br/> [REDACTED] 0839 <br/>BP: 127/82 <br/>Pulse: 86 <br/>Resp: 18 <br/>Temp: 36.1 °C (97 °F) <br/>TempSrc: Skin <br/>SpO2: 100% <br/>Weight: 111 kg (245 lb) <br/>Height: 1.867 m (73.5") <br/><br/>No data recorded <br/>Physical Exam<br/><br/> <br/>Labs:<br/>Lab Results <br/>Component Value Date <br/> WBC 7.5 [REDACTED] <br/> RBC 3.40 (L) [REDACTED] <br/> HGB 9.8 (L) [REDACTED] <br/> HCT 29.2 (L) [REDACTED] <br/> MCV 85.9 [REDACTED] <br/> MCHC 33.6 [REDACTED] <br/> RDW 19.5 (H) [REDACTED] <br/> PLT 183 [REDACTED] <br/> MPV 6.6 [REDACTED] <br/> NRBC 0.9 [REDACTED] <br/><br/>DIFF<br/>Lab Results <br/>Component Value Date <br/> LYMPHOPCT 24.9 [REDACTED] <br/> NEUTROABS 4.80 [REDACTED] <br/> LYMPHSABS 1.90 [REDACTED] <br/> MONOABS 0.70 [REDACTED] <br/> EOSABS 0.10 [REDACTED] <br/> BASOSABS 0.10 [REDACTED] <br/><br/>Lab Results <br/>Component Value Date <br/> NA 135 (L) [REDACTED] <br/> K 4.2 [REDACTED] <br/> CL 102 [REDACTED] <br/> CO2 24 [REDACTED] <br/> GLUCOSE 190 (H) [REDACTED] <br/> BUN 19 [REDACTED] <br/> CREATININE 0.71 [REDACTED] <br/> CALCIUM 8.4 (L) [REDACTED] <br/> PROT 6.5 [REDACTED] <br/> ALBUMIN 4.1 [REDACTED] <br/> BILITOT 0.6 [REDACTED] <br/> AST 15 [REDACTED] <br/> ALT 15 [REDACTED] <br/> ALKPHOS 146 (H) [REDACTED] <br/> EGFR 96 [REDACTED] <br/><br/> <br/>Pathology:<br/>n/a<br/> <br/>Diagnostic Imaging:<br/>Reviewed<br/> <br/>Assessment and Recommendations:<br/>[REDACTED] is a [REDACTED]. male with metastatic prostate cancer with history of on and off Lupron treatment possibly castrate resistant.<br/><br/>Prostate cancer continue docetacxekl chemo and nubeqa toleratign weel plan to continue for 6 total cycles.<br/> <br/> <br/>The patient was offered a follow-up visit [REDACTED] <br/> <br/>No orders of the defined types were placed in this encounter.<br/><br/>Requested Prescriptions <br/><br/> No prescriptions requested or ordered in this encounter <br/> <br/> <br/>COUNSELING:  The patient was counseled extensively.  We discussed the results of all recent diagnostic tests and what these results mean.  We discussed the prognosis of the disease.  We discussed the risks and benefits of the treatment plan at length.  The patient was given instruction for treatment and the follow up appointments were reviewed.  We reviewed all the medications and educated the patient about their appropriate uses.  The importance of compliance with all medications and instruction was emphasized.  <br/><br/>All aspects of the plan were discussed with the patient.  The patient was given opportunities to ask questions, which we answered.  We believe the patient agrees with the treatment plan<br/> <br/>[REDACTED], MD<br/>[REDACTED] <br/><br/></content><br/><span class="xLabel">Electronically signed by [REDACTED], MD at [REDACTED]  9:12 AM EDT</span><br/></content></li></ul>documented in this encounter</div><h3><a name="id6" href="#toc">Plan of Treatment</a></h3><div><table><span style="font-weight:bold; ">Upcoming Encounters</span><colgroup><col width="10%"/><col width="15%"/><col width="25%" span="3"/></colgroup><thead><tr><th>Date</th><th>Type</th><th>Department</th><th>Care Team (Latest Contact Info)</th><th>Description</th></tr></thead><tbody><tr ID="encounter36" class="xRowNormal"><td>[REDACTED]  8:40 AM EDT</td><td ID="encounter36type">Office Visit</td><td><p>HCMG Cancer Center Hematology Oncology</p><p>[REDACTED]</p><p>[REDACTED][REDACTED]</p><p>[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED]</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/></tr></tbody></table>documented as of this encounter</div><h3><a name="id7" href="#toc">Results</a></h3><div><ul><li>Prostate specific antigen ([REDACTED]  8:49 AM EDT): <table><colgroup><col width="20%"/><col width="12%"/><col width="8%"/><col width="20%"/><col width="10%" span="2"/><col width="20%"/></colgroup><thead><tr><th>Component</th><th>Value</th><th>Ref Range</th><th>Test Method</th><th>Analysis Time</th><th>Performed At</th><th>Pathologist Signature</th></tr></thead><tbody><tr ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727781.Comp1" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727781.Comp1Name">PSA</td><td>0.08</td><td>0.00 - 4.00 ng/mL</td><td><p>LAB CHEMISTRY METHOD</p></td><td>[REDACTED]  9:44 AM EDT</td><td>HOLY CROSS [REDACTED] FL (HCFL) HOSPITAL LAB</td><td ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727781.Comp1Signature"/></tr></tbody></table><table><colgroup><col width="20%" span="5"/></colgroup><thead><tr><th>Specimen (Source)</th><th>Anatomical Location / Laterality</th><th>Collection Method / Volume</th><th>Collection Time</th><th>Received Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727781.Specimen">Blood</td><td>Venous blood specimen / Unknown</td><td>Venipuncture / Unknown</td><td>[REDACTED]  8:49 AM EDT</td><td>[REDACTED]  9:03 AM EDT</td></tr></tbody></table><table><thead><tr><th>Narrative</th></tr></thead><tbody><tr><td class="xpre"><p>HOLY CROSS [REDACTED] FL (HCFL) HOSPITAL LAB - [REDACTED]  9:44 AM EDT</p><p><span class="content_span">NCCN Guidelines Prostate Cancer Early Detection </span><br/><span class="content_span"> </span><br/><span class="content_span">Age(yrs)  DRE Finding         PSA Level </span><br/><span class="content_span">          Normal              &lt; 1  ng/mL    Repeat 2-4 year intervals </span><br/><span class="content_span">45-75     Normal              1 - 3 ng/mL   Repeat 1-2 year intervals </span><br/><span class="content_span">          Very Suspicious     &gt; 3  ng/mL    See indications for biopsy </span><br/><span class="content_span"> </span><br/><span class="content_span">&gt;75*      Normal              &lt; 4 ng/mL     Repeat 1-4 year intervals </span><br/><span class="content_span">                                           (if no other indications for biopsy) </span><br/><span class="content_span">          Very Suspicious     &gt;= 4 ng/mL    See indications for biopsy </span><br/><span class="content_span"> </span><br/><span class="content_span">* Testing men &gt;75 yrs should be done with caution and only in very healthy men with little or no comorbidity as a large proportion may harbor cancer that would be unlikely to affect their life expectancy. </span><br/><span class="content_span"> </span><br/><span class="content_span">Indications for Biopsy** </span><br/><span class="content_span">- Repeat PSA                   - Consider % Free PSA, </span><br/><span class="content_span">- DRE, if not                    4Kscore or PHI            - TRUS-guided biopsy </span><br/><span class="content_span">performed during          &gt;&gt;&gt;  - Consider             &gt;&gt;&gt;  - Follow up in 6-12 </span><br/><span class="content_span">initial risk assessment          multiparametric MRI         months with PSA/DRE </span><br/><span class="content_span">- Workup for benign disease </span><br/><span class="content_span"> </span><br/><span class="content_span">**The level of PSA correlates with the risk of prostate cancer. The Prostate Cancer Prevention Trial (PCPT) demonstrated that 15% of men with a PSA level of &lt;=4.0 ng/mL and a normal DRE had prostate cancer diagnosed on end-of-study biopsies. Approximately 30% to 35% of men with serum PSA between 4 to 10 ng/mL will be found to have cancer. Total PSA levels &gt;10 ng/[REDACTED] a greater than 67% likelihood of prostate cancer. </span><br/><span class="content_span"> </span><br/><span class="content_span">Based on the National Comprehensive Cancer Network (NCCN) Guidelines </span><br/><span class="content_span">Version 2.2018 Prostate Cancer Early Detection. </span><br/><span class="content_span">______________________________________________________________________________</span><br/><span class="content_span"> </span><br/><span class="content_span">According to the reagent manufacturer, consumption of biotin supplements, or multivitamins containing biotin, may interfere with the results of this assay. For individuals taking biotin containing supplements, testing at least three days after cessation of supplement consumption is recommended.</span><br/><span class="content_span"> </span><br/><span class="content_span"> </span></p></td></tr></tbody></table><table><colgroup><col width="20%"/><col width="80%"/></colgroup><thead><tr><th>Authorizing Provider</th><th>Result Type</th></tr></thead><tbody><tr><td>[REDACTED] MD</td><td>LAB BLOOD ORDERABLES</td></tr></tbody></table><table><colgroup><col width="20%" span="3"/><col width="40%"/></colgroup><thead><tr><th>Performing Organization</th><th>Address</th><th>City/State/ZIP Code</th><th>Phone Number</th></tr></thead><tbody><tr><td ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727781.PerformingLab"><p>[REDACTED] FL (HCFL) HOSPITAL LAB</p></td><td><p>[REDACTED]</p></td><td><p>[REDACTED], [REDACTED]</p></td><td><p>[REDACTED]</p></td></tr></tbody></table></li><li>Prostate specific antigen ([REDACTED]  8:56 AM EDT): <table><colgroup><col width="20%"/><col width="12%"/><col width="8%"/><col width="20%"/><col width="10%" span="2"/><col width="20%"/></colgroup><thead><tr><th>Component</th><th>Value</th><th>Ref Range</th><th>Test Method</th><th>Analysis Time</th><th>Performed At</th><th>Pathologist Signature</th></tr></thead><tbody><tr ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727740.Comp1" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727740.Comp1Name">PSA</td><td>0.13</td><td>0.00 - 4.00 ng/mL</td><td><p>LAB CHEMISTRY METHOD</p></td><td>[REDACTED] 11:18 AM EDT</td><td>HOLY CROSS [REDACTED] FL (HCFL) HOSPITAL LAB</td><td ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727740.Comp1Signature"/></tr></tbody></table><table><colgroup><col width="20%" span="5"/></colgroup><thead><tr><th>Specimen (Source)</th><th>Anatomical Location / Laterality</th><th>Collection Method / Volume</th><th>Collection Time</th><th>Received Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727740.Specimen">Blood</td><td>Venous blood specimen / Unknown</td><td>Venipuncture / Unknown</td><td>[REDACTED]  8:56 AM EDT</td><td>[REDACTED]  9:13 AM EDT</td></tr></tbody></table><table><thead><tr><th>Narrative</th></tr></thead><tbody><tr><td class="xpre"><p>HOLY CROSS [REDACTED] FL (HCFL) HOSPITAL LAB - [REDACTED] 11:18 AM EDT</p><p><span class="content_span">NCCN Guidelines Prostate Cancer Early Detection </span><br/><span class="content_span"> </span><br/><span class="content_span">Age(yrs)  DRE Finding         PSA Level </span><br/><span class="content_span">          Normal              &lt; 1  ng/mL    Repeat 2-4 year intervals </span><br/><span class="content_span">45-75     Normal              1 - 3 ng/mL   Repeat 1-2 year intervals </span><br/><span class="content_span">          Very Suspicious     &gt; 3  ng/mL    See indications for biopsy </span><br/><span class="content_span"> </span><br/><span class="content_span">&gt;75*      Normal              &lt; 4 ng/mL     Repeat 1-4 year intervals </span><br/><span class="content_span">                                           (if no other indications for biopsy) </span><br/><span class="content_span">          Very Suspicious     &gt;= 4 ng/mL    See indications for biopsy </span><br/><span class="content_span"> </span><br/><span class="content_span">* Testing men &gt;75 yrs should be done with caution and only in very healthy men with little or no comorbidity as a large proportion may harbor cancer that would be unlikely to affect their life expectancy. </span><br/><span class="content_span"> </span><br/><span class="content_span">Indications for Biopsy** </span><br/><span class="content_span">- Repeat PSA                   - Consider % Free PSA, </span><br/><span class="content_span">- DRE, if not                    4Kscore or PHI            - TRUS-guided biopsy </span><br/><span class="content_span">performed during          &gt;&gt;&gt;  - Consider             &gt;&gt;&gt;  - Follow up in 6-12 </span><br/><span class="content_span">initial risk assessment          multiparametric MRI         months with PSA/DRE </span><br/><span class="content_span">- Workup for benign disease </span><br/><span class="content_span"> </span><br/><span class="content_span">**The level of PSA correlates with the risk of prostate cancer. The Prostate Cancer Prevention Trial (PCPT) demonstrated that 15% of men with a PSA level of &lt;=4.0 ng/mL and a normal DRE had prostate cancer diagnosed on end-of-study biopsies. Approximately 30% to 35% of men with serum PSA between 4 to 10 ng/mL will be found to have cancer. Total PSA levels &gt;10 ng/[REDACTED] a greater than 67% likelihood of prostate cancer. </span><br/><span class="content_span"> </span><br/><span class="content_span">Based on the National Comprehensive Cancer Network (NCCN) Guidelines </span><br/><span class="content_span">Version 2.2018 Prostate Cancer Early Detection. </span><br/><span class="content_span">______________________________________________________________________________</span><br/><span class="content_span"> </span><br/><span class="content_span">According to the reagent manufacturer, consumption of biotin supplements, or multivitamins containing biotin, may interfere with the results of this assay. For individuals taking biotin containing supplements, testing at least three days after cessation of supplement consumption is recommended.</span><br/><span class="content_span"> </span><br/><span class="content_span"> </span></p></td></tr></tbody></table><table><colgroup><col width="20%"/><col width="80%"/></colgroup><thead><tr><th>Authorizing Provider</th><th>Result Type</th></tr></thead><tbody><tr><td>[REDACTED] MD</td><td>LAB BLOOD ORDERABLES</td></tr></tbody></table><table><colgroup><col width="20%" span="3"/><col width="40%"/></colgroup><thead><tr><th>Performing Organization</th><th>Address</th><th>City/State/ZIP Code</th><th>Phone Number</th></tr></thead><tbody><tr><td ID="Result.1.2.840.114350.1.13.502.2.7.2.798268.1043727740.PerformingLab"><p>[REDACTED] FL (HCFL) HOSPITAL LAB</p></td><td><p>[REDACTED]</p></td><td><p>[REDACTED], US</p></td><td><p>[REDACTED]</p></td></tr></tbody></table></li></ul>documented in this encounter</div><h3><a name="id8" href="#toc">Visit Diagnoses</a></h3><div><table><colgroup><col width="100%"/></colgroup><thead><tr><th>Diagnosis</th></tr></thead><tbody><tr ID="vdx4" class="xRowNormal"><td><p><span class="content_span">Prostate cancer (CMS/HCC)</span><span class="content_span"> - Primary</span></p><p>Malignant neoplasm of prostate</p></td></tr><tr ID="vdx5" class="xRowAlt"><td><p><span class="content_span">Abnormal findings on diagnostic imaging of other specified body structures</span></p></td></tr><tr ID="vdx6" class="xRowNormal"><td><p><span class="content_span">Abnormal results of liver function studies</span></p><p>Nonspecific abnormal results of liver function study</p></td></tr><tr ID="vdx7" class="xRowAlt"><td><p><span class="content_span">Abnormal coagulation profile</span></p></td></tr></tbody></table>documented in this encounter</div><h3><a name="id9" href="#toc">Care Teams</a></h3><div><table ID="ct49"><colgroup><col width="25%" span="3"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Team Member</th><th>Relationship</th><th>Specialty</th><th>Start Date</th><th>End Date</th></tr></thead><tbody><tr class="xRowNormal"><td><p>[REDACTED], DO</p><p>NPI: [REDACTED]</p><p>[REDACTED]</p><p>[REDACTED]-2828</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td>PCP - General</td><td>Internal Medicine</td><td>[REDACTED]</td><td/></tr></tbody></table>documented as of this encounter</div><br/><br/>
</body></html>